p53 Abnormalities in adenocarcinoma of the gastric cardia and antrum

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 5, 1999, Pages 263-268

  Flejou J F ^a   Gratio, V ^b   Muzeau, F ^b   Hamelin, R ^c  

^a BEAUJON HOSPITAL   (France)

^b INSERM   (France)

^c FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Cardia; Gastric cancer; p53 gene; p53 protein

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CARDIA; CONTROLLED STUDY; DNA SEQUENCE; ESOPHAGUS CARCINOMA; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; STOMACH ANTRUM; STOMACH CANCER; TUMOR LOCALIZATION;

EID: 0032887447     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.5.263     Document Type: Article

References (44)

1. Morales TG. Adenocarcinoma of the gastric cardia. Dig Dis 1997;15:346-56.
2. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
3. Antonioli DA, Wang HH. Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997;26:495-506.
4. Forman D, Webb P, Parsonnet J. Helicobacter pylori and gastric cancer. Lancet 1994;343:243-4.
5. Souza RH, Meltzer SJ. The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:583-98.
6. Stemmerman G, Heffelfinger SC, Noffringer A, et al. The molecular biology of esophageal cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors. Hum Pathol 1994;25:968-81.
7. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996;23:307-15.
8. Fléjou J-F, Muzeau F, Potet F, et al. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas. Pathol Res Pract 1994;190:1141-8.
9. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol 1986;17:482-7.
10. Watanabe H, Jass JR, Sobin LH. Histological typing of oesophageal and gastric tumours, World Health Organisation international histological classification of tumours. Berlin: Springer-Verlag, 1990.
11. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand [A] 1965;64:31-49.
12. Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 1977;39:2475-85.
13. Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 1992;33:606-12.
14. Hermanek P, Sobin LH, eds. TNM classification of malignant tumours. Berlin: Springer-Verlag, 1992.
15. Baas IO, Mulder JWR, Offerhaus GJA, et al. An evaluation of six antibodies or immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
16. Hamelin R, Flejou J-F, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 1994;107:1012-18.
17. Renault B, Van Den Broek M, Fodde R, et al. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993;53:2614-17.
18. Seruca R, David L, Castedo S, et al. p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. Cancer Genet Cytogenet 1994;75:45-50.
19. Poremba C, Yandell DW, Huang Q, et al. Frequency and spectrum of p53 mutations in gastric cancer a molecular genetic and immunohistochemical study. Virchows Arch 1995;426:447-55.
20. Maesawa C, Tamura G, Suzuki Y, et al. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 1995;176:249-58.
21. Mönig SP, Eidt S, Zirbes TK, et al. p53 expression in gastric cancer. Clinicopathological correlation and prognostic significance. Dig Dis Sci 1997;42:2463-7.
22. Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21 (WAF1/CIP1/SDI1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinomas. Cancer 1997;79:2067-72.
23. Liang YY, Esteve A, Martel-Planche G, et al. p53 mutations in esophageal tumors from high-incidence areas of China. Int J Cancer 1995;61:611-14.
24. Gleeson CM, Soan JM, Mcmanus DT, et al. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer 1998;77:277-86.
25. Shun CT, Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-9.
26. Starzynska T, Bromley M, Ghosh A, et al. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
27. Gleeson CM, Sloan JM, Mcguigan JA, et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55:3406-11.
28. Levine DS. Barrett's esophagus and p53. Lancet 1994;344:212-13.
29. Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-95.
30. Johnson H, Belluco C, Masood S, et al. The value of flow cytometric analysis in patients with gastric cancer. Arch Surg 1993;128:314-17.
31. Muzeau F, Flejou J-F, Belghiti J, et al. Infrequent microsatellite instability in oesophageal cancers. Br J Cancer 1997;75:1336-9.
32. Gleeson CM, Sloan JM, Mcguigan JA, et al. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated oesophageal adenocarcinoma. Cancer Res 1996;56:259-63.
33. Gleeson CM, Sloan JM, Mcguigan JA, et al. Widespread microsatellite instability occurs infrequently in adenocarcinoma of the gastric cardia. Oncogene 1996;12:1653-62.
34. Dos Santos NR, Seruca R, Constancia M, et al. Microsatellite instability at multiple loci in gastric carcinoma: clinico-pathologic implications and prognosis. Gastroenterology 1996;110:38-44.
35. Van Dekken H, Geelen E, Dinjens WNM, et al. Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res 1999;59:748-52.
36. Wu TT, Watanabe T, Heitmiller R, et al. Genetic alterations in Barrett esophagus and adenotarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287-94.
37. Cameron AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-6.
38. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
39. Uchino S, Noguchi M, Ochiai A, et al. p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993;54:759-64.
40. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to pathogenesis: a review. Int J Cancer 1996;69:225-35.
41. Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994;57:1-9.
42. Hamelin R, Jego N, Laurent-Puig P, et al. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 1993;8:2213-20.
43. Gabbert HE, Muller W, Schneiders A, et al. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
44. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994;18:1247-53.